Head and neck carcinoma in the United States

Cancer, 05/09/2012

Ang KK et al. – Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN) documented differences in patient characteristics and treatments between community and academic settings for a large series of patients in the United States.


  • Patients aged ≥18years were enrolled in the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN) after providing written informed consent if they had a confirmed diagnosis of new HNC and were scheduled to receive treatment other than surgery alone.


  • Between 2005 and 2010, 100 centers enrolled 4243 patients, including 2612 patients (62%) from academic investigators and 1631 patients (38%) from community centers.
  • Initial treatments were radiation with concurrent chemotherapy (30%) or cetuximab (9%), adjuvant radiotherapy (21%), induction chemotherapy (16%), and other (24%).
  • Intensity modulated radiation therapy was the dominant radiation technique (84%).
  • Single-agent cisplatin was prescribed in nearly half of patients and more often in academic centers (53% vs 43% of patients; P<.0001).
  • Single-agent cetuximab was the next most common drug used (19%) and was prescribed more frequently in community settings (24% vs 17%; P=.0001).
  • The data rejected the 2 prospective hypotheses.

Print Article Summary Cat 2 CME Report